April 5 (Reuters) - The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson and Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer. (Reporting by Disha Mishra in Bengaluru; Editing by William Mallard)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
46 USD | +0.62% | +0.09% | -23.60% |
Apr. 23 | Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission | MT |
Apr. 22 | Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
149.5 USD | +0.35% | -0.30% | 358B | ||
46 USD | +0.62% | +0.09% | 8.32B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.60% | 8.32B | |
+2.50% | 108B | |
+9.56% | 105B | |
+1.57% | 23.46B | |
-11.82% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.85% | 17.19B | |
+5.95% | 13.99B | |
+34.84% | 12.53B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- U.S. FDA approves expanded use of J&J's cancer cell therapy